title: Cost-effectiveness of recombinant versus urinary follicle stimulating hormone; whose point of view?
authors.affiliation: Assisted Conception Unit, Birmingham Women's Hospital, Edgbaston, Birmingham, B15 2TG, UK. bolarinde.ola@bham-womens.thenhs.com
authors.forename: B
authors.initials: B
authors.lastname: Ola
authors.forename: M
authors.initials: M
authors.lastname: Afnan
authors.forename: K
authors.initials: K
authors.lastname: Sharif
authors.forename: N
authors.initials: N
authors.lastname: Hammadieh
authors.forename: S
authors.initials: S
authors.lastname: Papaioannou
authors.forename: A
authors.initials: A
authors.lastname: Coomarasamy
mesh_terms: D000328:Adult; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D005307:Fertilization in Vitro / Q000191:economics*; D005640:Follicle Stimulating Hormone / Q000191:economics*; D006801:Humans; D011994:Recombinant Proteins / Q000191:economics
chemical_list: D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone